Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of EXV-802 and EXV-801 for Agitation in Alzheimer's Disease Dementia
2024-517388-22-00Phase 3Authorised
- Sponsor
- Exciva
- Start
- Apr 2026
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing EXV-802, EXV-801 and Matching placebo (3 arms). Primary endpoint: Primary efficacy endpoint. Planned start Apr 2026; status: authorised.
02
Drugs
EXV-802deramciclane
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-517388-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517388-22-00.